Mumbai, July 23: Ranbaxy Laboratories, the country's top drugmaker by sales, said on Tuesday it has acquired a facility from New York-based Signature Pharma for producing medications in liquid form. The automated manufacturing and packaging facility with testing and quality assurance capabilities is the first liquid manufacturing unit of Ranbaxy in the United States, it said in a notice to the Bombay Stock Exchange.

"Signature's acquisition provides a strategic platform for Ranbaxy's US operations in liquid dosage forms," Ranbaxy president Brian Tempest said in a statement.

The cost of the acquisition was not disclosed. Bureau Report